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Abstract: Bioassay-guided isolation of the lipophilic extract of Trichodesmium thiebautii bloom material
led to the purification and structure characterization of two new hybrid polyketide-non-ribosomal
peptide (PKS-NRPS) macrocyclic compounds, tricholides A and B (1 and 2). A third macrocyclic
compound, unnarmicin D (3), was identified as a new depsipeptide in the unnarmicin family, given
its structural similarity to the existing compounds in this group. The planar structures of 1–3 were
determined using 1D and 2D NMR spectra and complementary spectroscopic and spectrometric
procedures. The absolute configurations of the amino acid components of 1–3 were determined
via acid hydrolysis, derivitization with Marfey’s reagent and HPLC-UV comparison to authentic
amino acid standards. The absolute configuration of the 3-hydroxydodecanoic acid moiety in 3 was
determined using a modified Mosher’s esterification procedure on a linear derivative of tricharmicin
(4) and additionally by a comparison of 13C NMR shifts of 3 to known depsipeptides with β-hydroxy
acid subunits. Tricholide B (2) showed moderate cytotoxicity to Neuro-2A murine neuroblastoma
cells (EC50: 14.5 ± 6.2 µM).
Keywords: Trichodesmium thiebautii; macrocycle; depsipeptide; cyanobacteria
1. Introduction
Marine cyanobacteria have been fertile grounds for the isolation of a diverse array of structurally
intriguing secondary metabolites with a broad-spectrum of biological activities [1–4]. A notable
class of these compounds are the macrocyclic hybrid polyketide-non-ribosomal peptides (PKS-NRPS).
The hybrid macrocycles isolated from cyanobacteria display unique and rare structural elements and
functionalities, such as the dichlorinated beta-hydroxy acid and thiazole carboxylic acid units in the
peptolide lyngbyabellin [5] and a rare N-methyl enamide of sanctolide A [6]. Macrocycles have been
prolific structures in drug discovery, perhaps most notably as antibiotics [7]. However, this class
displays diverse bioactivities including antitumor [8], antimalarial [9] and neuroactive properties,
including sodium channel inhibition [10].
Many cyanobacterial macrocycles are peptides and depsipeptides [11] derived from NRPS
or mixed NRPS-PKS genetic architecture and encode proteins with the ability to incorporate
L- and D-α-amino acids as well as β-hydroxy fatty acids [12,13]. β-hydroxyacyl incorporation
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has been observed in several microbial depsipeptides including the beauverolides [14–16]
(3 and 4 residue macrocycles); the unnarmicins [17], the solonamides [18], the arthroamides [19],
the turnagainolides [20], and ngercheumicin C, D and E [21] (five residue macrocycles);
and scytonemide B [22] and kailuin A-H (six residue macrocycles) [23,24]. These macrocycles have
generally displayed antibiotic activity [17], quorum sensing interference [18] and weak cytotoxicity [24].
In this work, we detail the isolation and structure characterization of three new additions (1–3) to
the PKS-NRPS macrocycles from Trichodesmium thiebautii bloom biomass. Trichodesmium spp. have
been a relatively underexplored source of secondary metabolites. The cyclic peptide trichamide
was isolated from a cultured specimen of Trichodesmium erythraeum IMS101 [25]. Trichophycin A
and the trichotoxins, chlorinated polyketides have been isolated from environmental collections of
Trichodesmium thiebautii [26,27]. Two of these metabolites in the current work, tricholides A and B
(1 and 2), represent a new class of polyketide macrolactones, each incorporating a single proline
residue and predicted 2-methylhexanoic acid residue. The third compound, unnarmicin D, departs
from previously described unnarmicins by featuring a 3-hydroxydodecanoic acid residue.
2. Results
2.1. Isolation and Structure Determination of 1–3
Bioassy-guided isolation of the lipophilic extract of Trichodesmium thiebautii bloom material using
human colon cancer HCT-116 cells identified a mixed fraction that showed potent cytotoxicity at a
single dose of 40 µg/mL. Subsequent purification of the fraction using HPLC resulted in the isolation
of 1. HRESIMS analysis of 1 identified a pseudomolecular ion [M + H]+ at m/z 408.3113 suggesting
a molecular formula of C24H41NO4 and five degrees of unsaturation. Examination of the 13C NMR,
HSQC and HMBC spectra identified two signals consistent with that of ester or amide functionalities,
two alkene signals, two oxymethine carbons, three methine carbons, eleven methylene signals, and
four methyl signals, one of which was consistent with that of an O-methyl (δC 56.0).
Examination of 1D and 2D NMR spectra (Figures S1–S7; Table 1) allowed for the construction
of two partial structures. In the first partial structure, a methine proton signal (H-2, δH 4.50) showed
COSY correlations to a diastereotopic methylene group (H-3a, δH 2.29 and H-3b, δH 2.10) and TOCSY
correlations to two additional methylene groups (H2-4, δH 1.94; H-5a, δH 3.77; H-5b, δH 3.62).
Examining the 13C NMR values of C-2, C-3, C-4, C-5 (δC 59.1, 31.8, 22.3, 46.7), we identified the
first spin system as the amino acid proline. An HMBC correlation from H-2 to C-1 (δC 172.2) firmly
established the α amino acid and satisfied two degrees of unsaturation. The second partial structure
was comprised of a polarized olefin (C-7, δC 117.1; C-8, δC 151.1) that showed HMBC correlations to
C-6 (δC 173.0) consistent with that of an α,β-unsaturated carbonyl functionality, satisfying the third
and fourth degree of unsaturation. The distal proton in the olefin (H-8, δH 7.16) showed a COSY
correlation to H-9 (δH 2.34). H-9 showed COSY correlations to a methyl signal (H-24, δH 1.04) and a
methylene (H2-10, δH 1.36). The H2-10 methylene signal was correlated by TOCSY to second methylene
group (H-11a, δH 1.62; H-11b, δH 1.43) and an oxymethine proton (H-12, δH 3.20). Bidirectional COSY
correlations established three methylene groups between H-12 and a second deshielded oxymethine
(H-16, δH 4.98). H-16 showed COSY correlations to H-17 (δH 1.60) and H-17 showed COSY correlations
to a methyl (H3-22, δH 0.91) and a methylene group (H-18a, δH 1.34; H-18b, δH 1.10). Bidirectional
COSY correlations from H2-18 to the terminal methyl H3-21 (δH 0.89) established two additional
methylene groups in the alkyl chain (H-19a, δH 1.30; H-19b, δH 1.26; H2-20, δH 1.28) and completed
the core of the second partial structure. An HMBC correlation from H3-23 (δH 3.27) to C-12 (δC 79.9)
established an O-methyl group in the second partial structure. HMBC correlations from H2-5 to C-6
connected the two partial structures and the HMBC correlation from H-16 to C-1 demonstrated that 1
was a macrolactone featuring a proline residue and satisfied the final degree of unsaturation (Figure 1).
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Table 1. NMR data for tricholide A (1) a (CDCl3).
Position δC δH (J in Hz) HMBC COSY
1 172.2, qC
2 59.1, CH 4.50, dd (9.0, 2.0) 1, 3, 4, 5 3a, 3b
3a 31.8, CH2 2.29, m 1, 2, 4 2, 3b, 4
3b 2.10, m 1, 4, 5 3a, 4
4 22.3, CH2 1.94, m 2, 3, 5 3a, 5a, 5b
5a 46.7, CH2 3.77, m 2, 3, 4, 6 4, 5b
5b 3.62, m 2, 3, 4, 6 4, 5a
6 165.2, qC
7 117.1, CH 5.84, d (15.5) 6, 8, 9, 24 8
8 151.1, CH 7.16, dd (15.5, 5.8) 6, 7, 9, 10, 24 7, 9
9 35.9, CH 2.34, m 7, 8, 10, 24 8, 10, 24
10 30.3, CH2 1.36, m 8, 9, 11 9
11a 30.9, CH2 1.62, m 10, 12 11b, 12
11b 1.43, ovlp b 10, 12 12
12 79.9, CH 3.20, m 11, 13, 14, 23 11b, 13a
13a 30.0, CH2 1.55, m 12, 14 12, 13b, 14b
13b 1.43, ovlp 12, 14 12, 13a, 14b
14a 19.6, CH2 1.40, m 13, 15, 16 13b, 14a
14b 1.16, m 15, 16 13a, 14a
15a 32.7, CH2 1.57, m 14, 16 14b, 15b, 16
15b 1.47, m 14, 16 14b, 15a, 16
16 78.3, CH 4.98, ddd (10.6, 4.6) 1, 14, 15, 17, 22 15a, 15b, 17
17 37.5, CH 1.60, m 16, 18, 19, 22 16, 18b, 22
18a 32.9, CH2 1.34, ovlp 17, 19 17, 18b
18b 1.10, m 17, 19 17, 18a
19a 29.2, CH2 1.30, ovlp 18, 20
19b 1.26, ovlp 18, 20 18b
20 22.9, CH2 1.28, ovlp 21 21
21 14.0, CH3 0.89, t (7.1) 19, 20 20
22 14.7, CH3 0.91, d (6.8) 16, 17, 18 17
23 56.0, CH3 3.27, s 12
24 22.5, CH3 1.04, d (7.0) 8, 9, 10 9
a 800 MHz for 1H, 200 MHz for 13C; b overlapping signals.
Mar. Drugs 2017, 15, 206  3 of 11 
 
Table 1. NMR data for tricholide A (1) a (CDCl3). 
Position  δC  δH (J in Hz) HMBC COSY 
1  172.2, qC       
2  59.1, CH  4.50, dd (9.0, 2.0)  1, 3, 4, 5  3a, 3b 
3a  31.8,  H2  2.29, m  1, 2, 4  2, 3b, 4 
3b    2.10, m  1, 4, 5  3a, 4 
4  22.3, CH2  1.94, m  2, 3,    3a, 5a, 5b 
5a  46.7, CH2  3.77, m  2, 3, 4, 6  4, 5b 
5b    3.62, m  2, 3, 4, 6  4, 5a 
6  165.2, qC       
7  117.1, CH  5.84, d (15.5)  6, 8, 9, 24  8 
8  151.1, CH  7.16, dd (15.5, 5.8)  6, 7, 9, 10, 24  7, 9 
9  35.9, CH  2.34, m  7, 8, 10, 24  8, 10, 24 
10  30.3, CH2  1.36, m  8, 9, 11  9 
11a  30.9, CH2  1.62, m  10, 1   11b, 12 
11b    1.4 , ovlp b  10,  2  12 
12  79.9,    3. 0, m  11, 13, 14, 23  11b, 13a 
13a  30.0, CH2  1.55, m  12, 14  12, 13b, 14b 
13b    1.43, ovlp  12, 14  12, 13a, 14b 
14a  19.6, CH2  1.40, m  13, 15, 16  13b, 14a 
14b    1.16, m  15, 16  13a, 14a 
15a  32.7, CH2  1.57, m  14, 16  14b, 15b, 16 
15b    1.47, m  14, 16  14b, 15a, 16 
16  78.3, CH  4.98, ddd (10.6, 4.6)  1, 14, 15, 17, 22    15a, 15b, 17 
17  3 .5, CH  1.60, m  6,  8,  9,    16, 18b, 22 
18a  32.9, CH2  1.34, ovlp  17, 19  17  18b 
18b    1.10, m  17, 19  17, 18a 
19a  29.2, CH2  1.30, ovlp  18, 20   
19b    1.26, ovlp  18, 20  18b 
20  22.9, CH2  1.28, ovlp  21  21 
21  14.0, CH3  0.89, t (7.1)  19, 20  20 
22  14.7, CH3  0.91, d (6.8)  16, 17, 18  17 
23  56.0, CH3  3.27, s  12   
24  22.5, CH3  1.04, d (7.0)  8, 9, 10  9 
a 800 MHz for 1H, 200  Hz for 13C; b overlapping signals. 
 
Figure 1. Structures of tricholide A (1), tricholide B (2) and unnarmicin D (3). The configuration of   
C‐16 and C‐17 in 1 and 2 is relative and noted by (*). 
HRESIMS of 2 identified a pseudomolecular ion [M + H]+ at m/z 422.3270 suggesting a molecular 
formula of C25H43NO4 and five degrees of unsaturation as in 1. The proton and carbon NMR spectra 
of 2 were nearly identical to 1 and the mass difference of 14 strongly suggested the addition of a CH2 
group or methyl group instead of a proton in 2. Examination of the 1H NMR, 13C NMR and 2D spectra 
of 2 (Figures S8–S14) showed a new singlet methyl signal (H3‐25, δH 1.84) instead of the doublet signal 
Figure 1. Structures of tricholide A (1), tricholide B (2) and unnarmicin D (3). The configuration of
C-16 and C-17 in 1 and 2 is relative and noted by (*).
HRESIMS of 2 identified a pseudomolecular ion [M + H]+ at m/ esting a olecular
formula of C25 43 4 fi i . r t and carbon R spectra
of 2 were nearly identical to 1 and the mas dif erence of 14 strongly sug ested the ad ition of a CH2
group or methyl group instead of a proton in 2. Examination of the 1H NMR, 13 R and 2D spectra
of 2 ) showed a new singlet methyl signal (H3-25, δH 1.84) instead of the doublet
signal H-7 (δH 7.16) in 1. The 13C NMR spectrum showed one new signal (C-25, δC 14.8) (Table S1).
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HMBC correlations from H3-25 to C-6, C-7 and C-8 firmly established the methyl substitution at
C-7 in 2.
The relative configuration of the olefin in 1 was determined to be E by virtue of the large vicinal
coupling constant between H-7 and H-8 (J = 15.5 Hz). The relative configuration between C-16 and
C-17 was determined by examining the extracted 1H-1H coupling constant between H-16 and H-17.
A large coupling constant of 10.6 Hz supported an anti-configuration. The relative configuration of 2
was identical to that of 1.
The absolute configuration of the proline residues in 1 and 2 was determined by comparing
the HPLC retention times of authentic L- and D/L-amino acid standards and the acid hydrolyzed
constituents of 1 and 2 each reacted with Marfey’s reagent (L-FDVA). The hydrolyzate of both 1 and 2
showed retention times (min) that matched L-Pro (13.00; see Experimental Section and Figures S22
and S23). The small quantities of 1 and 2 isolated precluded further analysis of absolute configuration.
HRESIMS analysis of 3 identified a pseudomolecular ion [M + H]+ at m/z 623.3436 suggesting
a molecular formula of C34H46N4O7 requiring 14 degrees of unsaturation. The peptidic nature of 3
was supported by five signals in the 13C NMR spectrum consistent with those of esters or amides
(δC 168.2, 170.1, 170.7, 171.3, 172.4) (Figure S16) and the examination of the 1H NMR spectrum with
doublets for four amide protons (δH 8.98, 8.61, 8.02 and 7.40) (Figure S15) accounting for five out of the
seven oxygen atoms present and the four nitrogen atoms.
Analysis of 2D NMR data (Figures S17–S21) allowed two spin systems to be established (cf. Table 2
and Figure 2) as likely Gly residues. COSY data correlated an NH proton (NH-3, δH 8.98) to a methine
proton (H-13, δH 4.13) which itself was correlated to a diastereotopic methylene group (H-14a, δH 3.02
and H-14b, δH 2.78). An HMBC correlation from the methylene group to a quaternary carbon (C-15,
δC 127.8) and chemically equivalent carbons (C-16/20, δC 129.8) established a connection to an aromatic
ring. The remaining carbons of the ring were comprised of chemically equivalent carbons (C-17/19,
δC 115.1) bearing methine protons (H-17/19, δH 6.69, d, J = 8.5 Hz) and a quaternary carbon (C-20,
δC 156.0) which strongly supported a Tyr residue. Additionally, COSY data correlated an NH proton
(NH-1, δH 7.40) to a methine proton (H-2, δH 4.58) which itself was correlated to a second diastereotopic
methylene group (H-3a, δH 3.15 and H-3b, δH 2.78). An HMBC correlation from this methylene group
to a quaternary carbon (C-4, δC 137.6) and 1H-1H couplings between five methine protons on this
second aromatic ring (C5–C9) supported a Phe residue. HMBC correlations from amino acid α-protons
to their adjacent carbonyls allowed the assignment of four unmodified amino acids: Phe, Tyr, and two
Gly residues (Figure 2). The presence of the two aromatic amino acids and five carbonyl functionalities
accounted for 13 out of the 14 degrees of unsaturation. The final residue was comprised of a deshielded
diastereotopic methylene group (H-24a, δH 2.60; H-24b, δH 2.19) which showed HMBC correlations to
the C-23 carbonyl (δC 170.7) and an oxygen-bearing methine (C-25, δC 72.5). The oxymethine proton
(H-25, δH 5.13) showed a COSY correlation to H2-26 (δH 1.54 and 1.46). Bidirectional HMBC and COSY
correlations in addition to examination of the 13C NMR spectrum extended the methylene chain to a
terminal methyl (H3-34, δH 0.87, t, J = 7.2 Hz). The 13C NMR spectrum showed four nearly chemically
equivalent carbon signals (C-28 and C-29, δC 28.9; C-30 and C-31 δC 28.7) correlated by HSQC to a
methylene envelope (δH 1.22–1.25). While the overlapping methylenes made NMR correlations of
individual signals difficult, the chemical shifts of these four remaining CH2 groups and the molecular
formula of 3 supported assigning this final residue as 3-hydroxydodecanoic acid (3-Hdda) (Table 2).
The individual residue spin systems of 3 were connected using HMBC data. An HMBC correlation
between the NH of Phe (NH-1, δH 7.40) and C-10 (δC 168.2) of Gly-1 connected these two residues.
An HMBC correlation between the NH proton (NH-2, δH 8.02) and C-12 (δC 171.3) connected Gly-1
to Tyr. The NH proton of Tyr (NH-3, δH 8.98) showed an HMBC correlation to the carbonyl of Gly-2
(C-21, δC 172.4) and the NH (NH-4, δH 8.61) of Gly-2 showed an HMBC correlation to C-23 (δC 170.7) of
the 3-Hdda residue. An HMBC correlation between the oxymethine H-25 (δH 5.14) and C-1 (δC 170.1)
connected the fatty acid residue to the Phe residue, satisfied the final degree of unsaturation and
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established 3 as a cyclic depsipeptide featuring a 3-hydroxy fatty acid moiety. Thus, the planar
structure of 3 was determined to be [3-Hdda-Gly-Tyr-Gly-Phe].
The absolute configuration of the α-amino acids in 3 were determined using the Marfey’s protocol
described above. The hydrolyzate of 3 showed retention times (min) that matched L-Phe (13.56) and
D-Tyr (11.93; see Experimental Section and Figure S24).
The absolute configuration of C-25 in the 3-Hdda residue was determined using a modified
Mosher’s esterification procedure [28] on a hydrolyzed linear derivative of unnarmicin D (4)
(Figures S25 and S26). Positive ∆(δHS-δHR) values for H-27 and H-26 and negative ∆(δHS-δHR)
values for H-24 and NH-4 supported an 25R configuration (Figure S27).
Table 2. NMR data for unnarmicin D (3) a (DMSO-d6).
Residue Position δC Type δH (J in Hz) HMBC COSY
Phe 1 170.1, qC
2 52.6 CH 4.58, td (9.5, 5.0) 1, 3, 4, 10 3a, 3b, NH-1
3a 36.5, CH2 3.15, dd (13.7, 5.0) 1, 2, 4, 5, 9 2, 3b
3b 2.78, ovlp 1, 2, 4, 5, 9 2, 3a
4 137.6, qC
5/9 129.3, CH 7.20, d (7.2) 3, 7
6/8 128.0, CH 7.24, t (7.2) 4, 5, 9
7 126.2, CH 7.17, t (7.2) 5, 9
NH-1 7.40, d (9.3) 2, 10 2
Gly-1 10 168.2, qC
11a 42.1, CH2 3.90, dd (17.1, 8.3) 10, 12 11b, NH-2
11b 3.37, dd (17.1, 4.6) 10, 12 11a, NH-2
NH-2 8.02, (8.4, 4.8) 11, 12 11a, 11b
Tyr 12 171.3, qC
13 57.2, CH 4.13, m 12, 14, 15, 21 14a, 14b, NH-3
14a 35.0, CH2 3.02, dd (14.3, 3.8) 12, 13, 15, 16, 20 13, 14b
14b 2.78, ovlp 12, 13, 15, 16, 20 13, 14a
15 127.8, qC
16/20 129.8, CH 7.13, d (8.5) 14, 18 17/19
17/19 115.1, CH 6.69, d (8.5) 15, 18 16/20
18 156.0, qC
NH-3 8.98, d (5.5) 13, 14, 21 13
Gly-2 21 172.4, qC
22a 42.7 CH2 3.83, dd (14.7, 3.8) 21, 23 22b, NH-4
22b 3.51, dd (14.7, 6.8) 21, 23 22a, NH-4
NH-4 8.61, dd (6.8, 3.9) 22, 23 22a, 22b
Hdda b 23 170.7, qC
24a 40.4, CH2 2.60, dd (13.7, 3.6) 23, 25, 26 24b, 25
24b 2.19, dd (13.7, 10.5) 23, 25, 26 24a, 25
25 72.5, CH 5.14, m 1, 24, 26, 27 24b, 26a, 26b
26a 33.8, CH2 1.54, m 24, 25, 27, 28 25, 26b, 27
26b 1.46, m 24, 25, 27, 28 25, 26a, 27
27 24.4, CH2 1.16, m 25, 26, 28 26a, 26b
28 28.9, CH2 1.22, ovlp c
29 28.9, CH2 1.22, ovlp
30 28.7, CH2 1.25, ovlp
31 28.7, CH2 1.25, ovlp
32 31.3, CH2 1.24, ovlp 31, 33, 34
33 22.1, CH2 1.28, m 32, 34 34
34 14.0, CH3 0.87, t (7.2) 32, 33 33
a 800 MHz for 1H, 200 MHz for 13C; b 3-hydroxydodecanoic acid; c overlapping signals.
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  4  137.6, qC      
 5/9  129.3, CH  7.20, d (7.2)  3, 7   
 6/8  128.0, CH  7.24, t (7.2)  4, 5, 9   
 7  126.2, CH  7.17, t (7.2)  5, 9   
 NH‐1    7.40, d (9.3)  2, 10  2 
Gly‐1  10  168.2, qC      
 11a  42.1, CH2  3.90, dd (17.1, 8.3)  10, 12  11b, NH‐2 
  11b    3.37, dd (17.1, 4.6)  10, 12  11a, NH‐2 
  NH‐2    8.02, (8.4, 4.8)  11, 12  11a, 11b 
Tyr  12  171.3, qC      
 13  57.2, CH  4.13, m  12, 14, 15, 21  14a, 14b, NH‐3 
  14a  35.0, CH2  3.02, dd (14.3, 3.8)  12, 13, 15, 16, 20  13, 14b 
  14b    2.78, ovlp  12, 13, 15, 16, 20  13, 14a 
  15  127.8, qC        
 16/20  129.8, CH  7.13, d (8.5)  14, 18  17/19 
  17/19  115.1, CH  6.69, d (8.5)  15, 18  16/20 
  18  156.0, qC      
 NH‐3    8.98, d (5.5)  13, 14, 21  13 
Gly‐2  21  172.4, qC      
 22a  42.7 CH2  3.83, dd (14.7, 3.8)  21, 23  22b, NH‐4 
  22b    3.51, dd (14.7, 6.8)  21, 23  22a, NH‐4 
  NH‐4    8.61, dd (6.8, 3.9)  22, 23  22a, 22b 
Hdda b  23  170.7, qC      
 24a  40.4, CH2  2.60, dd (13.7, 3.6)  23, 25, 26  24b, 25 
  24b    2.19, dd (13.7, 10.5)  23, 25, 26  24a, 25 
  25  72.5, CH  5.14, m  1, 24, 26, 27    24b, 26a, 26b 
  26a  33.8, CH2  1.54, m  24, 25, 27, 28  25, 26b, 27 
i r . l ti s f r 3.
2.2. Biological Evaluation of 1–3
No antibacterial activity was observed for 1–3 against the pathogenic strains used in this study
and 3 did not demonstrate a 50% reduction in cell viability against HCT-116 cells and Neuro-2A cells
(25 µM dose). Tricholides A (1) and B (2) did not show cytotoxic effects against HCT-116 cells at 25 µM.
However, 2 did show moderately potent cytotoxicity against Neuro-2A neuroblastoma cells (EC50:
14.5 ± 6.2 µM) (See Figure S28). 1 was not tested against Neuro-2A cells to preserve some amount as
a chemical standard. Further work will explore biological activities of 1–3 and search for additional
analogs from future Trichodesmium collections.
3. Discussion
Tricholides A and B (1 and 2) represent structurally intriguing new additions to macrocylic
PKS-NRPS molecules isolated from cyanobacteria collections. These molecules feature a core
15-membered macrolactone reminiscent of palmyrolide A [10] and the laingolides [29]. However, the
tricholides feature a 2-methylhexanoic moiety instead of an unusual t-butyl branch. Using Tanimoto
scoring and database searching, desulfated penarolide sulfate A1 was the most similar molecule to the
tricholides [30]. Penarolide A1 is a macrocylic polyketide featuring a single proline residue. However,
the core structure of penarolide A1 is a much larger 30-membered ring.
Unnarmicin D (3) showed significant structural similarity to the unnarmicins. 3 contains two
chiral amino acids, while the unnarmicins contains four chiral amino acids and 3 contains a longer
β-acyloxy chain than the unnarmicins. When comparing the amino acid and hydroxy acid sequences of
five residue depsipeptides with β-acyloxy functionalities a pattern emerges with respect to the absolute
configuration of the individual residues (Table 3). The acyloxy group is of the R configuration in all
molecules in Table 3 except for turnagainolide B, which contains a rare 3-hydroxy-5-phenyl-4-pentenoic
acid in the S configuration [20]. Following a predicted biosynthetic route, the first amino acid in
five-residue depsipeptides with β-acyloxy components is in the L-configuration, the second amino
acid is in the D-configuration. The third amino aci is in the L- or D-configuration and the final amino
acid is in the L-configuration. Configuration analysis of new metabolites in this class, and determining
the absolute configuration of unassigned compounds such as the ngercheumicins, will determine if
this pattern, with respect to absolute configurations, continues to hold true.
The configur tions of the acyloxy residue listed in all Table 3 examples were determined using
the Mosher’s method. A computational approach was employed in the configuration analysis of
the depsipeptide kailuin B, following equivocal results from derivative analysis using Mosher’s
method [24]. Theodore et al., used the 13C NMR chemical shifts of a diagnostic set of depsipeptides
containing β-acyloxy groups to provide key insights into 13C NMR δ values for configuration analysis.
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These 13C NMR values from experimental approaches were combined with computations using
density functional theory (DFT) calculations to identify key differences in the β and γ positions of the
β-acyloxy residue. A diagnostic assessment was proposed in which an R configuration is assigned
when δCβ ≤ 74/δCγ ≤ 36 while an S configuration is assigned when δCβ ≥ 77/δCγ ≥ 40. The 13C
NMR values for the β and γ positions of 3 are 72.5 ppm and 33.8 ppm respectively. Analysis of the
Mosher’s ester derivatives of 4 was challenging due to overlapping methylene signals in the Hdda
residue and we relied on differences in chemical shift values at H-27, H-26, H-24 and NH-4 for absolute
configuration determination. There was no apparent chemical shift difference at H-25. Utilizing the
diagnostic approach of Theodore et al., supports the value of these computational approaches and
additionally serves as an orthogonal approach to derivitization analysis.
Table 3. Five-residue depsipeptides from marine microbes containing β-hydroxy acid groups.
Compound Residue Sequence Source
Unnarmicin D (3) (R)-Hdda Gly D-Tyr Gly L-Phe environmental collection of T. thiebautii
Unnarmicin A [17] (R)-Hha a L-Leu D-Phe L-Leu L-Phe Photobacterium sp. strain MBIC0648517
Unnarmicin C [17] (R)-Hoa b L-Leu D-Phe L-Leu L-Phe Photobacterium sp. strain MBIC0648517
Solonamide A [18] (R)-Hha L-Phe D-Leu D-Ala L-Leu Photobacterium sp. strain S275318
Solonamide B [18] (R)-Hoa L-Phe D-Leu D-Ala L-Leu Photobacterium sp. strain S275318
Arthroamide [19] (R)-Hppa c L-Val D-Ala L-Val L-Val Arthrobacter sp. strain PGVB119
Turnagainolide A [20] (R)-Hppa L-Val D-Ala L-Ile L-Val Bacillus sp. strain RJA219420
Turnagainolide B [20] (S)-Hppa L-Val D-Ala L-Ile L-Val Bacillus sp. strain RJA219420
Ngercheumicin C [21] Hoa Phe Leu Leu Leu Photobacterium sp.
Ngercheumicin D [21] Hoa Phe Met Leu Leu Photobacterium sp.
Ngercheumicin E [21] Hoa Phe Phe Leu Leu Photobacterium sp.
a 3-hydroxy-hexanoic acid; b 3-hydroxy-octanoic acid; c 3-hydroxy-5-phenyl-4-pentenoic acid.
4. Materials and Methods
4.1. General Experimental Procedures
Optical rotations were measured using a Jasco P-2000 polarimeter (Jasco Inc., Easton, MD, USA).
UV spectra were measured using a Beckman Coulter DU-800 spectrophotometer (Beckman Coulter
Inc., Brea, CA, USA). NMR spectra were collected using a Bruker 800 MHz NMR instrument (Bruker,
Rheinstetten, Germany) equipped with a cryoprobe with CDCl3 and DMSO-d6 as the internal standard
(δC 77.0, δH 7.26; δC 39.5, δH 2.50). A Varian 500 MHz NMR spectrometer equipped with a 5 mm,
room temperature OneNMR probe was utilized for certain experiments (Varian Inc., Palo Alto, CA,
USA). HRESIMS analysis was performed using a AB SCIEX TripleTOF 4600 mass spectrometer (SCIEX,
Framingham, MA, USA) with Analyst TF software. Semi-preparative HPLC was carried out using a
Dionex Ultimate 3000 HPLC system equipped with a micro vacuum degasser, an autosampler and a
diode–array detector (Thermo Scientific, Waltham, MA, USA).
4.2. Collection of Biological Material
Samples from a localized bloom of Trichodesmium thiebautii were collected from Padre Island,
Corpus Christi, TX during 9–11 May 2014. Surface bloom material was collected in 5-g buckets from
ca. 0.5-m water depth. Approximately 300 g wet weight cell mass was concentrated from this material
and frozen for further chemical analysis. In the laboratory, a subsample of the cell mass was examined
microscopically and identified using Komarek (2002) [31].
4.3. Extraction and Isolation
The frozen biomass was thawed and extracted five times using 2:1 CH2Cl2/CH3OH, affording
3.95 g of crude extract. The crude extract was further fractionated over silica gel using vacuum liquid
chromatography (VLC) and a solvent system of increasing polarity using a stepped gradient from 100%
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hexanes to 100% CH3OH to generate 9 subfractions (A-I). Two fractions were combined (40% hexanes
in ethyl acetate (Fraction E) and 20% hexanes in ethyl acetate (Fraction F)) based on similarities in
their respective 1H NMR spectra. The combined fraction was evaporated under reduced pressure
and the resultant residue was applied to a 2 g C18 SPE column and eluted with 100% methanol to
remove exceedingly lipophilic constituents before HPLC separation. The fraction was subjected to
RP semi-preparative HPLC using a YMC 5 µm ODS column (250 × 10 mm); mobile phase: 85%
CH3CN/15% H2O with 0.05% formic acid added to each solvent, flow 3 mL/min and 0.3 mg of 1 (tR,
12.8 min) and 0.8 mg of 2 (tR, 14.0 min) were isolated. Two addition fractions, the first eluting with 100%
EtOAc (fraction G) and the second eluting with 25% CH3OH in EtOAc (fraction H) were combined
based on similarities in their 1H NMR spectra and dried using rotary evaporation. The residue was
applied to a 2 g C18 SPE column and fractionated using 50% CH3CN in H2O, 100% CH3CN and 100%
CH3OH. The fraction eluting with 100% CH3CN was subjected to RP semi-preparative HPLC using a
YMC 5 µm ODS column (250 × 10 mm); mobile phase: 70% CH3CN/30% H2O with 0.05% formic acid
added to each solvent, flow 3 mL/min and a fraction was collected from min 9.5–10.0. This fraction
was further purfied using a YMC 5 µm ODS column; mobile phase: 60% CH3CN/40% H2O with 0.05%
formic acid added to each solvent, flow 3 mL/min and 3.5 mg of 3 were isolated (tR, 19.0 min).
Tricholide A (1): colorless oil; [α]23D −10.4 (MeOH, c 0.09); UV (MeOH) λmax (log ε) 213 (3.9) nm 1H NMR
(800 MHz, CDCl3) and 13C NMR (200 MHz, CDCl3) see Table 1; HRESIMS m/z 408.3113 [M + H]+
(calcd. for C24H42NO4, 408.3114).
Tricholide B (2): colorless oil; [α]23D −10.8 (MeOH, c 0.09); UV (MeOH) λmax (log ε) 205 (3.5) nm 1H NMR
(800 MHz, CDCl3) and 13C NMR (200 MHz, CDCl3), see Table S1; HRESIMS m/z 422.3276 [M + H]+
(calcd. for C25H44NO4, 422.3270).
Unnarmicin D (3): white amorphous solids; [α]22D −53.3 (MeOH, c 0.07); UV (MeOH) λmax (log ε) 201
(4.09), 221 (3.76), 275 (3.02) nm; 1H NMR (800 MHz, DMSO-d6) and 13C NMR (200 MHz, DMSO-d6),
see Table 2; HRESIMS m/z 623.3436 [M + H]+ (calcd. for C34H47N4O7, 623.3445).
4.4. Acid Hydrolysis and Marfey’s Protocol
To determine the absolute configuration of the α-amino acids in 1–3, 0.2 mg of each compound
was reconstituted in 0.2 mL of 6 N HCl and heated at 110 ◦C for 15 h. The hydrolyzate was dried
in vacuo, reconstituted in 100 µL of 0.1 M NaHCO3 solution and treated with 50 µL of 1 mg/mL
solution of N-α-(2,4-dinitro-5-fluorophenyl)-L-valinamide (L-FDVA) in acetone, followed by heating
at 55 ◦C for 2 h, cooled to room temperature and quenched with 50 µL of 2 N HCl. The hydrolyzate
was dried in vacuo and reconstituted in 100 µL of 50% CH3CN/H2O + 0.1% formic acid (FA) and
filtered through 0.2 µm filter. The hydrolyzate and the L-FDVA derivatized α-amino acid standards
were subjected to HPLC analysis (20% CH3CN/H2O + 0.1% FA to 80% CH3CN/H2O + 0.1% FA over
30 min; Phenomenex Kinetex C18 column, 150 × 3 mm, flow 0.6 mL/min). The retention time (min)
of the hydrolyzate of 1 and 2 matched L-Pro (13.00; D-Pro, 14.50). The retention times (min) of the
hydrolyzate of 3 matched L-Phe (13.55; D-Phe, 16.18), and D-Tyr (11.75; L-Tyr, 10.45).
4.5. Hydrolysis of 3
Unnarmicin D (3) (3.0 mg) was dissolved in 5% sodium methoxide in CH3OH (2 mL) and stirred
for 30 min at room temperature. The reaction mixture was neutralized by adding 100 µL of 1 M HCl.
The mixture was evaporated under reduced pressure to remove CH3OH and 1 mL of H2O was added
to the slurry and extracted three times with EtOAc. After drying with over Na2SO4, the solvent was
removed under reduced pressure and the residue was filtered and subjected to RP-HPLC using a
YMC 5 µm ODS column (250 × 10 mm); mobile phase: 65% CH3CN/35% H2O with 0.05% formic acid
added to each solvent, flow 3 mL/min and 0.50 mg of 4 was isolated (tR, 7.0 min).
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Unnarmicin D linear derivative (4): white amorphous solids; 1H NMR (500 MHz, DMSO-d6) δ 0.85 (3H, t,
J = 7.2 Hz, Hdda, H-34), 1.16 (2H, m, Hdda, H-27) 1.21–1.26 (12H, ovlp, Hdda, H-28-H-33), 1.33 (2H, m,
Hdda, H-26), 2.20 (2H, m, Hdda, H-24), 2.63 (1H, m, Tyr, H-14b), 2.85 (1H, m, Tyr, H-14a), 2.87 (1H, m,
Phe, H-3b), 3.03 (1H, m, Phe, H-3a), 3.39 (1H, m, Gly-1, H-11b), 3.47 (1H, m, Gly-2, H-22b), 3.59 (1H, m,
Gly-2, H-22a), 3.75 (1H, m, Hdda, H-25), 3.80 (1H, m, Gly-1, H-11a), 4.34 (1H, m, Tyr, H-13) 6.61 (2H,
d, J = 8.5 Hz, Tyr, H-17/19), 6.96 (2H, d, J = 8.5 Hz, H-16/20) 7.11 (3H, ovlp, Phe, H-5/9, H-7), 7.15
(2H, m, Phe, H-6/8) 7.32 (1H, m, NH-1), 7.95 (1H, m, NH-3), 8.20 (1H, m, NH-2), 8.35 (1H, m, NH-4);
HRESIMS m/z 663.3366 [M + Na]+ (calcd. for C34H48N4O8, 663.3370).
4.6. Preparation of MTPA Esters of 4
0.25 mg of 4 was dissolved in dry CH2Cl2 (0.6 mL) in a 4 mL vial to which dry
pyridine (10 µL) and (S)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (15 µL) were
added. The identical procedure was repeated with an equal amount of 4 and (R)-(−)-α-methoxy-α-
(trifluoromethyl)phenylacetyl chloride. The vials were capped and the reaction mixtures were stirred
for 24 h. The reactions were quenched with H2O and separated using CH2Cl2 and H2O. The CH2Cl2
layer was evaporated under reduced pressure and the derivatives were subjected to 1H NMR analysis.
4.7. Antimicrobial Assay
4.7.1. Bacterial Strains
Methicillin-resistant Staphylococcus aureus (MRSA, ATCC 43300), Pseudomonas aeruginosa PAO1,
and Escherichia coli (ATCC 35218) were employed for antimicrobial activities.
4.7.2. Antimicrobial Activity
The antimicrobial properties of 1–3 were tested via broth dilution assay. Compounds were
prepared in DMSO at 5 mg/mL. Tetracycline and gentamycin were used as positive controls.
Minimal inhibitory concentrations (MICs) were determined using the broth microdilution method.
Briefly, pathogens were firstly inoculated into tryptic soy broth (TSB, BD, Franklin Lakes, NJ, USA) at
37 ◦C and shaken at 175 rpm overnight. The bacterial broth (1 × 108 colony-forming units (CFU)/mL)
was immediately diluted to 1 × 105 CFU/mL. In 96-well microtiter plates, 5 µL of compounds and
controls were mixed well with 195 µL of bacterial suspension (1:39 (v/v)). After a series of two-fold
dilutions, the microtiter plates were then incubated statically at 37 ◦C overnight. MICs were determined
as the minimal concentration at which no visible bacterial growth was present. No antimicrobial
activity was observed for compounds 1–3.
4.8. Cytotoxicity Assay
HCT-116 cells and Neuro-2A cells were added to 96 well plates in 100 µL of McCoy’s Media
and Eagle’s Minimum Essential Media (EMEM) respectively each supplemented with 10% FBS each
at a density of 5000 cells/well. Cells were incubated overnight (37 ◦C, 5% CO2) and examined
microscopically to confirm confluence and adherence. Purified 1–3 were dissolved in DMSO (1% v/v)
and added to the cells in the range of 100, 10, 1, 0.1 and 0.01 µM. Four technical replicates were prepared
for each concentration and the assay was performed in triplicate. Doxorubicin was used as the positive
control (EC50:Neuro-2A = 100 ± 5.2 nM). Plates were incubated for 72 h after which 15 µL of MTT dye
were added each assay well. The dye was allowed to incubate with the cells for 4 h after which the
media was aspirated and the remaining crystals were solubilized in 100 µL DMSO. The plates were
incubated at 37 ◦C for 30 min to allow the crystals to solubilize. Absorbance at 540 nm was measured
using a Molecular Devices SpectraMax plate reader and % viability was calculated compared to the
negative control (1% DMSO) and EC50 curves were generated using GraphPad Prism 6.
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Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/15/7/206/s1,
Table S1: NMR data for 2; Figures S1–S21: 1H NMR, 13C NMR, HSQC, HMBC, COSY, TOCSY and NOESY
spectra of 1–3; Figures S22–S24: Marfey’s L-FDVA derivatives of the hydrolyzate of 1–3 compared to L-FDVA
amino acid standards. Figures S25 and S26: 1H NMR and COSY of 4. S27: ∆(δHS-δHR) values of S-MTPA and
R-MTPA esters of 4. Figure S28. EC50 curve of 2 tested against Neuro-2A cells.
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